Healthcare provider profile · identity verified

Robert R. Faust, MD

Internal Medicine · BURLINGTON, MA · NPI 1093859407

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	945	295
Amlodipine Besylate	Amlodipine Besylate	522	161
Lisinopril	Lisinopril	479	149
Losartan Potassium	Losartan Potassium	332	101
Hydrochlorothiazide	Hydrochlorothiazide	325	99
Omeprazole	Omeprazole	273	88
Simvastatin	Simvastatin	257	78
Levothyroxine Sodium	Levothyroxine Sodium	248	77
Metoprolol Succinate	Metoprolol Succinate	244	80
Tamsulosin Hcl	Tamsulosin Hcl	205	64
Gabapentin	Gabapentin	193	46
Metformin Hcl	Metformin Hcl	163	49
Sertraline Hcl	Sertraline Hcl	160	55
Trazodone Hcl	Trazodone Hcl	148	41
Atenolol	Atenolol	143	48
Famotidine	Famotidine	143	42
Rosuvastatin Calcium	Rosuvastatin Calcium	142	53
Allopurinol	Allopurinol	138	38
Pantoprazole Sodium	Pantoprazole Sodium	137	45
Eliquis	Apixaban	124	30
Pravastatin Sodium	Pravastatin Sodium	115	38
Lorazepam	Lorazepam	104	34
Warfarin Sodium	Warfarin Sodium	100	32
Alprazolam	Alprazolam	99	22
Metformin Hcl Er	Metformin Hcl	94	30
Furosemide	Furosemide	89	28
Metoprolol Tartrate	Metoprolol Tartrate	81	27
Fluticasone Propionate	Fluticasone Propionate	71	35
Potassium Chloride	Potassium Chloride	65	17
Albuterol Sulfate Hfa	Albuterol Sulfate	64	30
Pregabalin	Pregabalin	60	13
Finasteride	Finasteride	57	19
Tramadol Hcl	Tramadol Hcl	55	16
Zolpidem Tartrate	Zolpidem Tartrate	51	11
Citalopram Hbr	Citalopram Hydrobromide	49	14
Xarelto	Rivaroxaban	49	16
Diazepam	Diazepam	48	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	45	13
Clonazepam	Clonazepam	44	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	41	suppressed
Glipizide	Glipizide	40	13
Fluoxetine Hcl	Fluoxetine Hcl	37	suppressed
Ibuprofen	Ibuprofen	36	13
Montelukast Sodium	Montelukast Sodium	35	12
Jardiance	Empagliflozin	34	12
Triamcinolone Acetonide	Triamcinolone Acetonide	34	15
Ozempic	Semaglutide	33	suppressed
Synthroid	Levothyroxine Sodium	33	suppressed
Valsartan	Valsartan	33	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	30	suppressed
Klor-Con M20	Potassium Chloride	29	11
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Lovastatin	Lovastatin	27	suppressed
Prednisone	Prednisone	27	14
Ezetimibe	Ezetimibe	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Verapamil Er	Verapamil Hcl	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Glipizide Er	Glipizide	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	20	17
Meloxicam	Meloxicam	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Rybelsus	Semaglutide	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Amoxicillin	Amoxicillin	17	13
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Carvedilol	Carvedilol	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Erythromycin	Erythromycin Base	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Oxcarbazepine	Oxcarbazepine	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Azithromycin	Azithromycin	15	suppressed
Felodipine Er	Felodipine	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Klor-Con M10	Potassium Chloride	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Baclofen	Baclofen	12	suppressed
Estazolam	Estazolam	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Lipitor	Atorvastatin Calcium	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Niacin Er	Niacin	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Temazepam	Temazepam	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error